RxDoctor Payments Data

Kiet Loc, MD

Neurology · Laguna Hills, CANPI 1609041581

Payments from drug & device makers

$19,036in general payments, 2019–2025

Across 862 payments — averaging $22.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • AbbVie$2K
  • Neurocrine Biosciences, Inc.$2K
  • Biogen$1K
  • Argenx US, Inc.$922
  • Amgen$795
  • plus $10K from 53 others

What the payments were for

  • Food & beverage$18,85899%
  • Education$1781%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.79$2,218
AbbVie(2 entities)119$1,922
Neurocrine Biosciences, Inc.66$1,532
Biogen63$1,455
Argenx US, Inc.34$922
Amgen(2 entities)29$795
Pfizer40$776
Lundbeck LLC41$775
Lilly USA, LLC36$717
AstraZeneca(2 entities)31$707
SK Life Science, Inc.34$638
Eisai Inc.25$597
EMD Serono, Inc.26$552
Octapharma USA, Inc.11$523
Teva Pharmaceuticals USA, Inc.29$467
Takeda Pharmaceuticals U.S.A., Inc.13$325
Otsuka America Pharmaceutical, Inc.14$314
MDD US Operations, LLC7$226
Merz Pharmaceuticals, LLC7$207
CSL Behring10$198
Grifols USA, LLC8$189
Amneal Pharmaceuticals LLC10$187
Livanova USA, Inc.9$186
Johnson & Johnson10$178
Axsome Therapeutics, Inc.6$176
Bristol Myers Squibb6$151
Tanabe Pharma America, Inc.7$135
Novartis5$135
Boston Scientific7$134
Kyowa Kirin, Inc.6$126
ANI Pharmaceuticals, Inc.4$121
Corium, LLC5$120
Avion Pharmaceuticals7$118
Adamas Pharmaceuticals, Inc.5$117
Ipsen Biopharmaceuticals, Inc4$109
Genentech USA, Inc.4$96
Sanofi5$95
Averitas Pharma Inc.3$77
Alnylam Pharmaceuticals Inc.3$71
GE HealthCare3$71
Scilex Pharmaceuticals Inc.4$68
Abbott4$55
Biohaven Pharmaceuticals, Inc.3$53
Upsher-smith Laboratories LLC2$49
Revance Therapeutics, Inc.2$41
Xeris Pharmaceuticals, Inc.2$35
Vanda Pharmaceuticals Inc.1$33
Alfasigma USA, Inc.2$32
Acadia Pharmaceuticals Inc1$26
Impel Pharmaceuticals LLC1$26
Avanir Pharmaceuticals, Inc.1$24
Vertical Pharmaceuticals, LLC1$23
Insightec,inc1$22
Biotronik Inc.1$18
Strongbridge US Inc.1$18
Azurity Pharmaceuticals, Inc.1$17
Arbor Pharmaceuticals, Inc.1$17
Impel Pharmaceuticals Inc.1$17
Dynasplint Systems Inc.1$6

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,036 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$336,922
Medicare patients
515
Services billed
4,666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UltomirisRavulizumab-Cwvz13$972,141
Gamunex-CImmune Globul G/Gly/Iga Avg 4638$398,016
CopaxoneGlatiramer Acetate16$148,393
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5013$110,457
RexultiBrexpiprazole32$62,485
Aimovig AutoinjectorErenumab-Aooe32$37,950
Memantine Hcl515$19,808
Nurtec OdtRimegepant Sulfate13$12,474
Carbidopa-LevodopaCarbidopa/Levodopa163$9,063
Donepezil Hcl500$5,915
Pregabalin206$5,758
Rivastigmine31$5,482
Gabapentin268$5,376
Primidone120$4,737
Entacapone25$3,924

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaUltomiris$707$972,14113 claims
Grifols USA, LLCGamunex-C$189$398,01638 claims
Teva Pharmaceuticals USA, Inc.Copaxone$467$148,39316 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$325$110,45713 claims
Otsuka America Pharmaceutical, Inc.Rexulti$314$62,48532 claims
PfizerNurtec Odt$776$12,47413 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$187$2,57320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,996 neurology providers in California.

Other neurology in Laguna Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →